New hope for transplant patients: drug may tame chronic GVHD without steroids

NCT ID NCT04294641

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug ibrutinib as a first treatment for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the recipient's body after a stem cell transplant. Ten adults took ibrutinib daily for up to 2 years to see if it could control the disease without using steroids. The goal was to measure how many patients had a complete or partial response at 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GVHD

Contacts and locations

Show contact details

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Washington University, School of Medicine

St Louis, Missouri, 63110, United States